RNTX Rein Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: RNTX
Price (delayed)
$1.11
Market cap
$24.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.17
Enterprise value
$17.16M
Highlights
The EPS is up by 10% since the previous quarter
Rein Therapeutics's net income has increased by 2.6% from the previous quarter
RNTX's quick ratio has shrunk by 53% YoY and by 45% QoQ
Rein Therapeutics's equity has decreased by 45% YoY and by 8% QoQ
Key stats
What are the main financial stats of RNTX
Market
Valuations
Earnings
Shares outstanding
22.15M
Market cap
$24.59M
Enterprise value
$17.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$63.52M
Net income
-$61.27M
EBIT
-$62.82M
EBITDA
-$62.81M
Free cash flow
-$23.2M
Per share
Balance sheet
Liquidity
EPS
-$3.17
EPS diluted
-$3.17
Free cash flow per share
-$1.06
Book value per share
$2.3
Revenue per share
$0
TBVPS
$0.42
Total assets
$57.63M
Total liabilities
$7.75M
Debt
$0
Equity
$49.88M
Working capital
$2.35M
Debt to equity
0
Current ratio
1.39
Quick ratio
1.24
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-73.5%
Return on equity
-81.6%
Return on invested capital
N/A
Return on capital employed
-121.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNTX stock price
How has the Rein Therapeutics stock price performed over time
Intraday
-4.72%
1 week
-23.97%
1 month
-23.45%
1 year
-48.85%
YTD
-51.74%
QTD
-20.71%
Financial performance
How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$63.52M
Net income
-$61.27M
Gross margin
N/A
Net margin
N/A
Rein Therapeutics's net income has increased by 2.6% from the previous quarter
The operating income has increased by 2.5% since the previous quarter
Price vs fundamentals
How does RNTX's price correlate with its fundamentals
Growth
What is Rein Therapeutics's growth rate over time
Valuation
What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 10% since the previous quarter
RNTX's P/B is 60% below its 5-year quarterly average of 1.2 and 40% below its last 4 quarters average of 0.8
Rein Therapeutics's equity has decreased by 45% YoY and by 8% QoQ
Efficiency
How efficient is Rein Therapeutics business performance
The ROE has plunged by 141% YoY and by 11% from the previous quarter
The ROA has plunged by 136% YoY and by 10% from the previous quarter
Dividends
What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNTX.
Financial health
How did Rein Therapeutics financials performed over time
RNTX's quick ratio has shrunk by 53% YoY and by 45% QoQ
RNTX's current ratio has dropped by 51% year-on-year and by 42% since the previous quarter
The debt is 100% smaller than the equity
Rein Therapeutics's equity has decreased by 45% YoY and by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.